← 產業報告目錄
Small Interfering RNA (siRNA) Therapeutics Market Size, Share & Trends Analysis Report By Delivery (Lipid Nanoparticles (LNPs), Conjugates), by Indication (Hereditary Transthyretin-mediated Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hypercholesterolemia, Others), by RoA (Intravenous (IV), Subcutaneous), By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-15頁數 178報告編號 INSIGHTACE-b3a70cd3c0
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Small Interfering RNA (siRNA) Therapeutics Market stood at USD 1.6 Bn in 2023, and is forecasted to reach USD 4.89 Bn by 2031, recording a CAGR of 15.0% from 2024 through 2031.
Small Interfering RNA (siRNA) Therapeutics covers reshaping how healthcare entities approach this space.
Several factors contribute to this trajectory, including heightened requirement next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, fueled by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Small Interfering RNA (siRNA) Therapeutics Market Snapshot
Chapter 4. Global Small Interfering RNA (siRNA) Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Small Interfering RNA (siRNA) Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
Chapter 5. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:
5.2.1. Onpattro (Patisiran)
5.2.2. Givlaari (Givosiran)
5.2.3. Oxlumo (Lumasiran)
5.2.4. Leqvio (Inclisiran)
5.2.5. Amvuttra (Vutrisiran)
5.2.6. Rivfloza (Nedosiran)
5.2.7. Wainua (Eplontersen)
5.2.8. Others
Chapter 6. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 2: By Delivery Method, Estimates & Trend Analysis
6.1. Market Share by Delivery Method, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Method:
6.2.1. Lipid Nanoparticles (LNPs)
6.2.2. GalNAc-Conjugates
6.2.3. Other Delivery Systems
Chapter 7. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 3: By Indication,
Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Hereditary Transthyretin-mediated Amyloidosis
7.2.2. Acute Hepatic Porphyria
7.2.3. Primary Hyperoxaluria Delivery 1
7.2.4. Primary Hypercholesterolemia
7.2.5. Others
Chapter 8. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 4: By RoA, Estimates & Trend Analysis
8.1. Market Share by RoA, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following RoA:
8.2.1. Intravenous (IV)
8.2.2. Subcutaneous
Chapter 9. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 5: By End-user, Estimates & Trend Analysis
9.1. Market Share by End-user, 2024 & 2034
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-user:
9.2.1. Hospitals and Clinics
9.2.2. Research Institutions
9.2.3. Pharmaceutical and Biotechnology Companies
9.2.4. Academic Institutions
Chapter 10. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Small Interfering RNA (siRNA) Therapeutics Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.2.3. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.2.4. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.2.5. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.2.6. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.3. Europe
10.3.1. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.3.3. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.3.4. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.3.5. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.3.6. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.4.3. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.4.4. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.4.5. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.4.6. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.5. Latin America
10.5.1. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.5.3. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.5.4. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.5.5. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.5.6. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.6.3. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.6.4. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.6.5. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.6.6. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Companies with Approved Products:
11.2.1.1. Alnylam Pharmaceuticals
11.2.1.2. Novartis
11.2.1.3. Dicerna Pharmaceuticals (Novo Nordisk)
11.2.1.4. Ionis Pharmaceuticals
11.2.1.5. AstraZeneca
11.2.2. In Clinical Trials:
11.2.2.1. Arrowhead Pharmaceuticals
11.2.2.2. Silence Therapeutics
11.2.2.3. Wave Life Sciences
11.2.2.4. Sirnaomics
11.2.2.5. Sylentis S.A.
11.2.2.6. Quark Pharmaceuticals
11.2.2.7. Arbutus Biopharma
11.2.2.8. Phio Pharmaceuticals
11.2.2.9. Benitec Biopharma
11.2.2.10. Bio-Path Holdings
11.2.3. Companies With Delivery Platforms:
11.2.3.1. ABL Bio
11.2.3.2. Arbutus Biopharma
11.2.3.3. Calando Pharmaceuticals
11.2.3.4. Genecon Biotechnologies
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們